ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Explore concise, expert-led educational activities delivering the latest updates from ACC 2026. This series highlights emerging science, late-breaking data, and evolving treatment strategies across cardiovascular care. Gain practical insights into how new evidence is shaping clinical decision-making and improving patient outcomes.
1-6 of 6
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
CardiologyPrimary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Value of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
CardiologyValue of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
- advertisement
